EC Neurology

Review Article Volume 16 Issue 12 - 2024

Growth Factors, Cell Receptors, Intracellular Kinases, and Transcription Factors Associated with Bipolar Disorder

AJ Russo1*, Albert Mensah2 and Judith Bowman2

1Visiting Professor, Hartwick College, Oneonta, NY and Research Director, Mensah Research Institute, Warrenville, Il, USA 2Mensah Research Institute, Warrenville, Il, USA

*Corresponding Author: AJ Russo, Visiting Professor, Hartwick College, Oneonta, NY and Research Director, Mensah Research Institute, Warrenville, Il, USA.
Received: November 07, 2024; Published: December 03, 2024



Bipolar disorder (BD) is a complex psychiatric condition characterized by extreme mood swings, including manic and depressive episodes. A growing body of research has highlighted the role of various growth factors, cell receptors, intracellular kinases, and transcription factors associated with the etiology of BP. This review summarizes many of the cellular factors related to BP.

 Keywords: Bipolar Disorder (BD); Growth Factors; Cell Receptors; Intracellular Kinases; Transcription Factors

  1. Wu YC., et al. “Associations between serum brain-derived neurotrophic factors and bipolar disorder”. Neuropsychiatry6 (2017).
  2. Munkholm K., et al. “Peripheral blood brain-derived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-analysis”. Molecular Psychiatry2 (2015): 216-228.
  3. Li Z., et al. “Brain-derived neurotrophic factor levels and bipolar disorder in patients in their first depressive episode: 3-year prospective longitudinal study”. British Journal of Psychiatry1 (2014): 29-35.
  4. Goldstein BI., et al. “Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders”. Journal of Child and Adolescent Psychopharmacology5 (2011): 479-484.
  5. Teh CA., et al. “Bipolar disorder, brain-derived neurotrophic factor (bdnf) val66met polymorphism and brain morphology”. PLoS ONE7 (2012): e38469.
  6. Grande Í., et al. “Val66met polymorphism and serum brain‐derived neurotrophic factor in bipolar disorder: an open‐label trial”. Acta Psychiatrica Scandinavica5 (2013): 393-400.
  7. González-Castro TB., et al. “The role of brain‐derived neurotrophic factor (bdnf) val66met genetic polymorphism in bipolar disorder: a case–control study, comorbidities, and meta‐analysis of 16,786 subjects”. Bipolar Disorders1 (2014): 27-38.
  8. Rigal A., et al. “Lower plasma vascular endothelial growth factor a in major depressive disorder not normalized after antidepressant treatment: a case control study”. Australian and New Zealand Journal of Psychiatry4 (2019): 402-408.
  9. Russo AJ. “Decreased serum hepatocyte growth factor (HGF) in individuals with bipolar disorder normalizes after zinc and anti-oxidant therapy”. Nutrition and Metabolic Insights 3 (2010): 49-55.
  10. Russo AJ and Lakshmi Anubrolu. “Decreased phosphorylated ERK 1/2 related to GABA levels in bipolar disorder”. Journal of Life Science and Biotechnology (2022): 126-132.
  11. Görgülü Y., et al. “Comparison of serum bdnf, il-1β, il-6, tnf-α, crp and leucocyte levels in unipolar mania and bipolar disorder”. Acta Neuropsychiatrica6 (2021): 317-322.
  12. Gideons E., et al. “Chronic lithium treatment elicits its antimanic effects via bdnf-trkb dependent synaptic downscaling”. Elife 6 (2017): e25480.
  13. Mamoor S. “Gene expression changes associated with electroconvulsive therapy (ect)”. (2020).
  14. Heberlein A., et al. “Bdnf plasma levels decrease during benzodiazepine withdrawal in patients suffering from comorbidity of depressive disorder and benzodiazepine dependence”. Psychopharmacology2 (2010): 213-215.
  15. Clinton SM and Meador‐Woodruff JH. “Abnormalities of the nmda receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder”. Neuropsychopharmacology7 (2004): 1353-1362.
  16. Bitanihirwe BK., et al. “N‐methyl‐d‐aspartate receptor expression in parvalbumin‐containing inhibitory neurons in the prefrontal cortex in bipolar disorder”. Bipolar Disorders1 (2010): 95-101.
  17. Ehrlich A., et al. “Alterations of cerebral glutamate in the euthymic state of patients with bipolar disorder”. Psychiatry Research: Neuroimaging2 (2015): 73-80.
  18. Yüksel Ç and Öngür D. “Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders”. Biological Psychiatry9 (2010): 785-794.
  19. Dunn FA., et al. “Sensory experience shapes the development of the visual system’s first synapse”. Neuron5 (2013): 1159-1166.
  20. Chua J., et al. “Functional remodeling of glutamate receptors by inner retinal neurons occurs from an early stage of retinal degeneration”. Journal of Comparative Neurology5 (2009): 473-491.
  21. Woo TW., et al. “N-methyl-d-aspartate receptor and calbindin-containing neurons in the anterior cingulate cortex in schizophrenia and bipolar disorder”. Biological Psychiatry9 (2008): 803-809.
  22. Fatemi SH., et al. “Expression of gabaa α2-, β1- and ɛ-receptors are altered significantly in the lateral cerebellum of subjects with schizophrenia, major depression and bipolar disorder”. Translational Psychiatry9 (2013): e303.
  23. Mitterauer B. “Downregulation and upregulation of glial connexins may cause synaptic imbalances responsible for the pathophysiology of bipolar disorder”. CNS Neuroscience and Therapeutics5 (2011): 281-293.
  24. Polan MB., et al. “Neurodevelopmental disorders among individuals with duplication of 4p13 to 4p12 containing a gabaa receptor subunit gene cluster”. European Journal of Human Genetics1 (2013): 105-109.
  25. Gibbons AS., et al. “Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects”. Journal of Affective Disorders3 (2009): 184-191.
  26. Cannon DM., et al. “Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder”. Archives of General Psychiatry7 (2006): 741-747.
  27. Wieck A., et al. “Menstrual cycle effects on hypothalamic dopamine receptor function in women with a history of puerperal bipolar disorder”. Journal of Psychopharmacology2 (2003): 204-209.
  28. Li X., et al. “Regulation of glycogen synthase kinase‐3 during bipolar mania treatment”. Bipolar Disorders7 (2010): 741-752.
  29. Polter A., et al. “Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances”. Neuropsychopharmacology 8 (2010): 1761-1774.
  30. Gould TD., et al. “Ar-a014418, a selective gsk-3 inhibitor, produces antidepressant-like effects in the forced swim test”. The International Journal of Neuropsychopharmacology4 (2004): 387-390.
  31. Abrial E., et al. “Protein kinase c inhibition rescues manic-like behaviors and hippocampal cell proliferation deficits in the sleep deprivation model of mania”. International Journal of Neuropsychopharmacology2 (2015): pyu031.
  32. Ahmad A., et al. “Endoxifen: a new, protein kinase c inhibitor to treat acute and mixed mania associated with bipolar i disorder”. Bipolar Disorders6 (2021): 595-603.
  33. Soeiro-de-Souza MG., et al. “Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder”. Acta Psychiatrica Scandinavica5 (2012): 332-341.
  34. Westman J., et al. “Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden”. BMJ Open4 (2013): e002373.
  35. Hahn C., et al. “Aberrant intracellular calcium signaling in olfactory neurons from patients with bipolar disorder”. American Journal of Psychiatry3 (2005): 616-618.
  36. Kelly E., et al. “Diacylglycerol kinase (dgka) regulates the effect of the epilepsy and bipolar disorder treatment valproic acid in Dictyostelium discoideum”. Disease Models and Mechanisms9 (2018).
  37. Rao S., et al. “Beneficial effect of phosphatidylcholine supplementation in alleviation of hypomania and insomnia in a Chinese bipolar hypomanic boy and a possible explanation to the effect at the genetic level”. SpringerPlus1 (2015): 235.
  38. Roman KM., et al. “Involvement of the nuclear factor-κb transcriptional complex in prefrontal cortex immune activation in bipolar disorder”. Translational Psychiatry1 (2021): 40.
  39. Rao J., et al. “Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients”. Molecular Psychiatry4 (2009): 384-392.
  40. Pinacho R., et al. “The transcription factor sp4 is reduced in postmortem cerebellum of bipolar disorder subjects: control by depolarization and lithium”. Bipolar Disorders5-6 (2011): 474-485.
  41. Mao X., et al. “Glutamate receptor activation evokes calpain‐mediated degradation of sp3 and sp4, the prominent sp‐family transcription factors in neurons”. Journal of Neurochemistry5 (2006): 1300-1314.
  42. Davis B., et al. “Tcf4 mutations disrupt synaptic function through dysregulation of rimbp2 in patient-derived cortical neurons” (2023).
  43. Pinacho R., et al. “Transcription factor sp4 phosphorylation is altered in the postmortem cerebellum of bipolar disorder and schizophrenia subjects”. European Neuropsychopharmacology10 (2015): 1650-1660.
  44. Del-Favero J., et al. “European combined analysis of the ctg18.1 and the erda1 cag/ctg repeats in bipolar disorder”. European Journal of Human Genetics4 (2002): 276-280.
  45. Saumya Pandey. “CRISPR-Cas Gene-Editing for Precision-Medicine Based “Neuro-Oncogenomics” in Immunotherapeutic Targeting of Wnt/Frizzled-Toll Like Receptors-Autophagy: Cost-Effective Management of Schizophrenia, Obsessive Compulsive Disorder, Alzheimer’s Disease and Glioblastoma in Genetically Disparate Susceptible Population-Pools in in the Covid-19 Vaccination Era”. EC Clinical and Medical Case Reports2 (2023): 12-14.
  46. Pandey S. “IL-6 induced upregulation of T-type Ca2+ currents and sensitization of DRG nociceptors is attenuated by MNK inhibition: Translational Research Perspective”. Journal of Neurophysiology1 (2020): 305-306.
  47. Pandey S. “Artificial intelligence and neuro-medicine: emerging trends in bipolar disorder, glioblastoma and Alzheimer’s disease”. Neurology and Neurotherapy 2 (2023): 000178.

AJ Russo., et al. “Growth Factors, Cell Receptors, Intracellular Kinases, and Transcription Factors Associated with Bipolar Disorder”. EC Neurology  16.12 (2024): 01-08.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net